Particle.news

INFevo Raises More Than ¥100 Million in Pre‑A Round to Scale Virtual‑Cell Platform

The funding will speed construction of a recursive scientific‑discovery system that pairs the OCOO virtual‑cell model with automated high‑throughput wet labs to prioritize and validate biological hypotheses.

Overview

  • INFevo said it completed a Pre‑A financing round of more than ¥100 million, led by new investors including Xinglian Capital and Prosperity7 Ventures with follow‑on investments from Shunwei Capital, Sequoia China and others.
  • The company presented a roadmap to pour the money into AI for Science infrastructure, high‑throughput automation and the Recursive Scientific Discovery (RSD) framework to make research outputs reusable.
  • INFevo described OCOO‑T, its transcriptome‑based virtual‑cell model, as posting industry‑leading results on the Tahoe100M, Replogle and PBMC single‑cell perturbation benchmarks in same‑condition tests.
  • The firm says its platform creates a closed loop where model predictions guide which wet‑lab perturbations to run and experimental data then retrains models to speed target finding, virtual screening and early efficacy assessment.
  • All technical claims and the financing details are based on the company’s disclosure and have not been independently verified, but the move highlights a wider industry push to pair AI models with automated labs to ease wet‑lab throughput limits and speed early drug discovery.